Bacterial Outer Membrane Vesicles Suppress Tumor by Interferon-γ-mediated Antitumor Response

Overview

Journal Nat Commun

Specialty Biology

Date 2017 Sep 22

PMID 28931823

Citations 209

Authors

Oh Youn Kim

Hyun Taek Park

Nhung Thi Hong Dinh

Seng Jin Choi

Jaewook Lee

Ji Hyun Kim

Seung-Woo Lee

Yong Song Gho

Affiliations

Soon will be listed here.

Abstract

Gram-negative bacteria actively secrete outer membrane vesicles, spherical nano-meter-sized proteolipids enriched with outer membrane proteins, to the surroundings. Outer membrane vesicles have gained wide interests as non-living complex vaccines or delivery vehicles. However, no study has used outer membrane vesicles in treating cancer thus far. Here we investigate the potential of bacterial outer membrane vesicles as therapeutic agents to treat cancer via immunotherapy. Our results show remarkable capability of bacterial outer membrane vesicles to effectively induce long-term antitumor immune responses that can fully eradicate established tumors without notable adverse effects. Moreover, systematically administered bacterial outer membrane vesicles specifically target and accumulate in the tumor tissue, and subsequently induce the production of antitumor cytokines CXCL10 and interferon-γ. This antitumor effect is interferon-γ dependent, as interferon-γ-deficient mice could not induce such outer membrane vesicle-mediated immune response. Together, our results herein demonstrate the potential of bacterial outer membrane vesicles as effective immunotherapeutic agent that can treat various cancers without apparent adverse effects.Bacterial outer membrane vesicles (OMVs) contain immunogens but no study has yet examined their potential in treating cancer. Here, the authors demonstrate that OMVs can suppress established tumours and prevent tumour metastasis by an interferon-γ mediated antitumor response.

Citing Articles

Unveiling the wonders of bacteria-derived extracellular vesicles: From fundamental functions to beneficial applications.

Rima M, Dakramanji M, El Hayek E, El Khoury T, Fajloun Z, Rima M Heliyon. 2025; 11(4):e42509.

PMID: 40028522 PMC: 11869109. DOI: 10.1016/j.heliyon.2025.e42509.

Enhanced Cancer Immunotherapy by Bacterial Cytoplasmic Membranes Coated Nanovaccines for Co-Delivery of Ovalbumin Antigen and Immune Adjuvants to Dendritic Cells in Lymph Nodes.

Zhao P, Fan Y, Wang Z, Tang H, Tian Y, Zhang Y Int J Nanomedicine. 2025; 20:2289-2304.

PMID: 40007905 PMC: 11853991. DOI: 10.2147/IJN.S496873.

Leveraging Microorganisms to Combat Skin Cancer.

Oyler H, Callister A, Kutch M, Wakefield M, Fang Y Microorganisms. 2025; 13(2).

PMID: 40005824 PMC: 11858759. DOI: 10.3390/microorganisms13020462.

Bacterial membrane-modified cerium oxide nanoboosters enhance systemic antitumor effects of radiotherapy in metastatic triple-negative breast cancer.

Chen S, Ng P, Lai C, Wang F, Wang Y, Chen M J Nanobiotechnology. 2025; 23(1):105.

PMID: 39940015 PMC: 11823237. DOI: 10.1186/s12951-025-03187-3.

Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy.

Li G, Pu S, You L, Gao Y, Zhong Y, Zhao H Pharmaceutics. 2025; 17(1).

PMID: 39861706 PMC: 11768367. DOI: 10.3390/pharmaceutics17010058.

References

Sharma P, Allison J . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015; 161(2):205-14. PMC: 5905674. DOI: 10.1016/j.cell.2015.03.030. View

Schwechheimer C, Kuehn M . Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015; 13(10):605-19. PMC: 5308417. DOI: 10.1038/nrmicro3525. View

Parker B, Rautela J, Hertzog P . Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016; 16(3):131-44. DOI: 10.1038/nrc.2016.14. View

Kim O, Lee J, Gho Y . Extracellular vesicle mimetics: Novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines. Semin Cell Dev Biol. 2016; 67:74-82. DOI: 10.1016/j.semcdb.2016.12.001. View

Lizotte P, Wen A, Sheen M, Fields J, Rojanasopondist P, Steinmetz N . In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer. Nat Nanotechnol. 2015; 11(3):295-303. PMC: 4777632. DOI: 10.1038/nnano.2015.292. View

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

Chen Q, Xu L, Liang C, Wang C, Peng R, Liu Z . Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy. Nat Commun. 2016; 7:13193. PMC: 5078754. DOI: 10.1038/ncomms13193. View

Ali O, Verbeke C, Johnson C, Warren Sands R, Lewin S, White D . Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants. Cancer Res. 2014; 74(6):1670-81. PMC: 3959905. DOI: 10.1158/0008-5472.CAN-13-0777. View

10.

Kim O, Hong B, Park K, Yoon Y, Choi S, Lee W . Immunization with Escherichia coli outer membrane vesicles protects bacteria-induced lethality via Th1 and Th17 cell responses. J Immunol. 2013; 190(8):4092-102. DOI: 10.4049/jimmunol.1200742. View

11.

Moynihan K, Opel C, Szeto G, Tzeng A, Zhu E, Engreitz J . Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med. 2016; 22(12):1402-1410. PMC: 5209798. DOI: 10.1038/nm.4200. View

12.

Yanez-Mo M, Siljander P, Andreu Z, Bedina Zavec A, Borras F, Buzas E . Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015; 4:27066. PMC: 4433489. DOI: 10.3402/jev.v4.27066. View

13.

Kim O, Choi S, Jang S, Park K, Kim S, Choi J . Bacterial protoplast-derived nanovesicles as vaccine delivery system against bacterial infection. Nano Lett. 2014; 15(1):266-74. DOI: 10.1021/nl503508h. View

14.

Kim J, Lee J, Park J, Gho Y . Gram-negative and Gram-positive bacterial extracellular vesicles. Semin Cell Dev Biol. 2015; 40:97-104. DOI: 10.1016/j.semcdb.2015.02.006. View

15.

Nokleby H, Aavitsland P, OHallahan J, Feiring B, Tilman S, Oster P . Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007; 25(16):3080-4. DOI: 10.1016/j.vaccine.2007.01.022. View

16.

He C, Duan X, Guo N, Chan C, Poon C, Weichselbaum R . Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. Nat Commun. 2016; 7:12499. PMC: 4992065. DOI: 10.1038/ncomms12499. View

17.

Schoenborn J, Wilson C . Regulation of interferon-gamma during innate and adaptive immune responses. Adv Immunol. 2007; 96:41-101. DOI: 10.1016/S0065-2776(07)96002-2. View

18.

Sharma P, Allison J . The future of immune checkpoint therapy. Science. 2015; 348(6230):56-61. DOI: 10.1126/science.aaa8172. View

19.

Vizcaino J, Cote R, Csordas A, Dianes J, Fabregat A, Foster J . The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2012; 41(Database issue):D1063-9. PMC: 3531176. DOI: 10.1093/nar/gks1262. View

20.

Gregory A, Titball R, Williamson D . Vaccine delivery using nanoparticles. Front Cell Infect Microbiol. 2013; 3:13. PMC: 3607064. DOI: 10.3389/fcimb.2013.00013. View